Drug Details

General Information of the Drug (ID: DR4154)
Name
Thymidine kinase/ganciclovir
Disease Cytomegaloviral disease [ICD-11: 1D82] Approved [1]
DrugBank ID
DB01004
Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally
    α. A List of Natural Product(s) Able to Enhance the Efficacy of This Drug
          Resveratrol      Gnetum parvifolium     Click to Show/Hide the Molecular Data of This NP
                 Achieving Therapeutic Synergy     Click to Show/Hide
                    Representative Experiment Reporting the Effect of This Combination [2]
                    Detail(s)  Combination Info  click to show the detail info of this combination
                    In-vitro Model B16 CVCL_F936 Mouse melanoma Mus musculus
                    In-vivo Model B16TK cells and B16 cells were mixed at a 3:7 ratio and subcutaneously inoculated the right flank of the pathogen-free C57BL/6 J mice (18-22 g).
                    Experimental
                    Result(s)		 Resveratrol could synergistically enhance the killing effect of TK/GCV suicide gene system in melanoma B16 cells and transplanted melanoma.
Target and Pathway
Target(s) Herpes simplex virus DNA polymerase UL30 (HSV UL30)  Molecule Info  [3]
Thymidine kinase 1 (TK1)  Molecule Info  [3]
Thymidine kinase 2 (TK2)  Molecule Info  [3]
References
Reference 1 FDA Approved Drug Products from FDA Official Website.
Reference 2 Synergistic inhibitory effect of resveratrol and TK/GCV therapy on melanoma cells. J Cancer Res Clin Oncol. 2020 Jun;146(6):1489-1499.
Reference 3 Ganciclovir. Profiles Drug Subst Excip Relat Methodol. 2018;43:1-208.
 Download Picture         KEGG Link